We need a new paradigm in gynecologic cancer care: SGO proposes solutions for delivery, quality and reimbursement policies.

Alvarez RD, Gray HJ, Timmins PF 3rd, Gibb RK, Edelson M, Fowler JM, Havrilesky LJ, McCauley DL, Nash JD, Rahaman J, Rash JK, Rodabaugh KJ, Powell MA, Bristow RE, Brown JV, Tewari D, Cliby WA, Anastasia P, Robinson WR 3rd, Shahin MS, Cantrell LA, Cloven NG, Gold MA, Hope JM, Muntz HG, Sorosky JI, Elkas JC, Frumovitz MM, Jewell E, Spillman MA, Naumann RW

The commercialization of robotic surgery: unsubstantiated marketing of gynecologic surgery by hospitals.

Schiavone MB, Kuo EC, Naumann RW, Burke WM, Lewin SN, Neugut AI, Hershman DL, Herzog TJ, Wright JD

The role of lymphadenectomy in endometrial cancer: was the ASTEC trial doomed by design and are we destined to repeat that mistake?

Naumann RW

The role of the phosphatidylinositol 3-kinase (PI3K) pathway in the development and treatment of uterine cancer.

Naumann RW

Management strategies for recurrent platinum-resistant ovarian cancer.

Naumann RW, Coleman RL

Peripheral neuropathy in patients with gynecologic cancer receiving chemotherapy: patient reports and provider assessments.

Kiser DW, Greer TB, Wilmoth MC, Dmochowski J, Naumann RW

Practice patterns of intraperitoneal chemotherapy in women with ovarian cancer.

Naumann RW, Sukumvanich P, Edwards RP

Uterine papillary serous carcinoma: state of the state.

Naumann RW

Can surgical staging affect the postoperative treatment and outcome of patients with endometrial cancer?

Naumann RW

Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

Mutch DG, Orlando M, Goss T, Teneriello MG, Gordon AN, McMeekin SD, Wang Y, Scribner DR Jr, Marciniack M, Naumann RW, Secord AA